Documents

$316M royalty acquisition in Parkinson's therapy drives growth, cash flow, and portfolio strength.

Record Q2 growth, strong liquidity, and strategic asset monetization drive robust outlook.

Diversified royalty portfolio, strong cash flow, and $3B+ pipeline drive sustained growth.

Trustees elected, all motions approved, and strong financial results with growth focus for 2026.

Record Q1 income and EBITDA margin achieved, with robust portfolio and enhanced capital flexibility.

Diversified royalty portfolio, strong cash flow, and robust pipeline drive sustainable growth.

Record financials, margin expansion, and strong pipeline drive robust 2026 growth outlook.

Strong Q3 growth, high margins, and new TED royalty deal drive positive outlook.

Internalization, strong Orserdu/Xolair, and Ectorly approval offset Bonjour/Omidria headwinds.

Internalization and strong cash flow position the Trust for long-term value creation.

Record cash receipts and income in 2024, with strong guidance and portfolio growth for 2025.

Cash receipts up 54% year-over-year, with expanded credit and major new transactions completed.